Based on our findings, physicians could develop guidelines for risk management and physical examinations in AD patients with SARS-CoV-2 infections, such as a pathogenic examination of cognitive decline and a test of serum levels of IL-6 and TNFa. This evidence concerns the gene IL6 and Alzheimer disease.